X-linked adrenoleukodystrophy: First report of the Italian Study Group

Neurological Sciences

Volumn 19, Issue 5, 1998, Pages 315-319

  Di Biase, A ^a   Salvati, S ^a   Avellino, C ^a   Cappa, M ^b   Bertini, E ^b   Moroni, I ^c   Rimoldi, M ^c   Uziel, G ^c  

^a Laboratory of Metabolism and Pathological Biochemistry   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Adrenoleukodystrophy; Adrenomyeloneuropathy; Bone marrow transplantation; Dietary treatment; Incidence; Phenotype; Very long chain fatty acids

Indexed keywords

ADOLESCENT; ADRENOLEUKODYSTROPHY; ADULT; ARTICLE; CHILD; FEMALE; GENETICS; HUMAN; ITALY; MALE; PATHOPHYSIOLOGY; PHENOTYPE;

ADOLESCENT; ADRENOLEUKODYSTROPHY; ADULT; CHILD; FEMALE; HUMANS; ITALY; MALE; PHENOTYPE;

EID: 0032173648     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf00713859     Document Type: Article

References (23)

1. Mosser J, Douar AM, Sarde CO, Kioschis P, Feil R, Moser H, Poustka AM, Mandel JM, Aubourg P (1993) Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporter. Nature 361:726-730
2. Wanders RJA, Van Roermund CWT, Van Wijland MJA et al ( 1988) Direct evidence that the deficient oxidation of very long chain fatty acids in X-linked adrenoleukodystrophy is due to an impaired ability of peroxisomes to activate very long chain fatty acids. Biochem Biophys Res Commun 153:618-624
3. Whitcomb RW, Linehan WM, Knazek RA (1988) Effects of long-chain saturated fatty acids on membrane microviscosity and adrenocorticotropin responsiveness of human adrenocortical cells in vitro. J Clin Invest 81:185-188
4. Di Biase A, Avellino C, Pieroni F, Quaresima T, Grisolia A, Cappa M, Salvati S (1997) Effect of exogenous hexacosanoic acid on biochemical myelin composition in weaning and postweaning rats. Neurochem Res 22:327-331
5. Powers JM, Liu Y, Moser A, Moser HW (1992) The inflammatory myelinopathy of adrenoleukodystrophy: Cells, effector molecules and pathogenetic implications. J Neuropathol Exp Neurol 51:630-643
6. Griffin DE, Moser HW, Mendoza Q, Moench T, O'Toole S, Moser AB (1985) Identification of the inflammatory cells in the nervous system of patients with adrenoleukodystrophy. Ann Neurol 18:660-664
7. Moser HW, Moser AB, Frayerk K, Chen W, Schulman JD, O'Neill BP (1981) Adrenoleukodystrophy: Increased plasma content of saturated very long chain fatty acids. Neurology 31:1241-1249
8. Di Biase A, Salvati S, Quaresima T, Pieroni F, Grisolia A, Cambiaso P, Cappa M (1995) C24:0/C22:0 ratio in plasma sphingomyelin as a practical tool for the diagnosis of adrenoleukodystrophy and adrenomyeloneuropathy. Clin Chem Enzym Commun 7:35-40
9. Murphy JV, Marquardt KM, Moser UW, Van Duyn MA (1982) Treatment of adrenoleukodystrophy by diet and plasmapheresis. Ann Neurol 12:220-223
10. Naidu S, Bresnan MJ, Griffin D, O'Toole S, Moser HW (1988) Intensive immunosuppression fails to alter neurological progrès-sion in childhood adrenoleukodystrophy. Arch Neurol 45:846-849
11. Cappa M, Bertini E, Del Balzo P, Cambiaso P, Di Biase A, Salvati S (1994) High dose of immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry 57[Suppl]:69-70
12. Rizzo WB, Phillips MW, Dammann AL, Leshner RT, Jennings SS et al (1987) Adrenoleukodystrophy: Dietary oleic acid lowers hexacosanoate levels. Ann Neurol 21:232-239
13. Uziel G, Bertini E, Bardelli P, Rimoldi M, Gambetti M (1991) Experience on therapy of adrenoleukodystrophy and adrenomyelopathy. Dev Neurosci 13:274-279
14. Moser HW (1995) Adrenoleukodystrophy: Natural history, treatment and outcome. J Inherit Metab Dis 18:435-447
15. Sereni C, Paturneau-Jouas M, Aubourg P, Baumann N, Feingold J (1993) Adrenoleukodystrophy in France: An epidemiological study. Neuroepidemiology 12:229-233
16. Moser HW (1995) Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy. J Neuropathol Exp Neurol 54:740-745
17. Aubourg P, Mandel JL ( 1996) X-linked adrenoleukodystrophy. Ann N YAcad Sei 804:461-476
18. Moser HW (1997) Adrenoleukodystrophy: Phenotype, genetics, pathogenesis and therapy. Brain 120:1485-1508
19. Van Geel BM, Assies J, Weverrling GJ, Earth PG (1994) Predominance of the adrenomyeloneuropathy phenotype of Xlinked adrenoleukodystrophy in the Netherlands. Neurology 4:2343-2346
20. Heim P, Claussen M, Hoffmann B, Conzelmann E, Gärtner J, Harzer K, Hunneman DH, Kohler W, Kuriemann G, Kohllschutter A (1997) Leukodystrophy incidence in Germany. Am J Med Genet 71:475-478
21. Bezman L, Moser HW (1998) Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes. Am J Med Genet 76:415-419
22. Moser HW, Tutschka PJ, Brown FR III, Moser AE, Yaeger AM et al (1984) Bone marrow transplant in adrenoleukodystrophy. Neurology 34:1410-1417
23. Aubourg P, Blanche S, Jambaque I, Rocchiccioli F, Kalifa G et al (1990) Reversal of early neurologic and neuroradiologic manifestation of X-linked adrenoleukodystrophy by bone marrow transplantation. New Engl J Med 322:1860-1866